Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 5Sarcoma 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Doxorubicin 11Cyclophosphamide 11Biopsy 9Radiation 8atezolizumab 7Temozolomide 7X-Rays 6Vincristine 6Nivolumab 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5fludarabine 5cabozantinib 5Sirolimus 5Radiotherapy 5Phantoms, Imaging 5Irinotecan 5Immunoglobulin G 5Ifosfamide 5Disulfides 5pembrolizumab 4Nuclear Medicine Department, Hospital 4temsirolimus 3palbociclib 3olaparib 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Asparaginase × Sarcoma × 30 days × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡